JP2005187344A - Agent for recovering cerebral fatigue - Google Patents

Agent for recovering cerebral fatigue Download PDF

Info

Publication number
JP2005187344A
JP2005187344A JP2003427401A JP2003427401A JP2005187344A JP 2005187344 A JP2005187344 A JP 2005187344A JP 2003427401 A JP2003427401 A JP 2003427401A JP 2003427401 A JP2003427401 A JP 2003427401A JP 2005187344 A JP2005187344 A JP 2005187344A
Authority
JP
Japan
Prior art keywords
fatigue
cerebral
cerebral fatigue
recovering
test
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003427401A
Other languages
Japanese (ja)
Inventor
Toshiro Kawanami
俊郎 河南
Yukitaka Tanaka
幸隆 田中
Eiichi Hoshino
栄一 星野
Yoshikazu Ogura
義和 小倉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kao Corp
Original Assignee
Kao Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kao Corp filed Critical Kao Corp
Priority to JP2003427401A priority Critical patent/JP2005187344A/en
Publication of JP2005187344A publication Critical patent/JP2005187344A/en
Pending legal-status Critical Current

Links

Images

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

<P>PROBLEM TO BE SOLVED: To provide a medicine for recovering cerebral fatigue, such as numerating ability deterioration caused by the cerebral fatigue. <P>SOLUTION: This medicine for recovering the cerebral fatigue based on high mental activity characteristic to human being contains theanine as an active ingredient. The medicine for recovering the cerebral fatigue is taken at a dose of 30 to 2,500 mg/day/person before or after a high mental action. <P>COPYRIGHT: (C)2005,JPO&NCIPI

Description

本発明は、ヒトに固有の高度な精神的活動(例えば計算能力、コンピュター作業、連続思考等)による疲労、すなわち大脳疲労を回復させるための薬剤に関する。   The present invention relates to an agent for recovering fatigue, that is, cerebral fatigue caused by a high level of mental activities inherent in humans (for example, computational ability, computer work, continuous thinking, etc.).

疲労は、通常、精神疲労と肉体疲労に大きく分類される。現代社会においては、肉体的疲労よりも精神的な疲労がもたらす影響の方がとりわけ深刻になってきている。疲労回復剤としては各種ビタミンやミネラル等の栄養補給剤が用いられているが、実際上は肉体疲労時の栄養補給を目的としている。一方、精神疲労に対する効果効能をもった疲労回復剤については未だ知られていない。   Fatigue is usually broadly classified into mental fatigue and physical fatigue. In modern society, the effects of mental fatigue are more serious than physical fatigue. Nutritional supplements such as various vitamins and minerals are used as fatigue recovery agents, but in practice, the purpose is to supplement nutrition during physical fatigue. On the other hand, a fatigue recovery agent having an effect on mental fatigue is not yet known.

テアニンの薬理作用としては、マウスにおいて、カフェインによって誘発されるけいれん死や運動量の増加に対して拮抗する作用(非特許文献1及び2)、イソプロテレノールによる心拍数上昇に対する抑制作用、ストレス負荷による血圧及び心拍数上昇に対する抑制作用(特許文献2)、ラットにおける神経細胞内のCa2+濃度を上昇させる作用(特許文献3)、カフェイン及びアルギニンとの併用により運動負荷後の集中力低下等を防止する作用(特許文献4)及びカフェイン及びアルギニンとの併用により運動負荷後のカテコールアミンを上昇させる作用(特許文献5)等が知られているが、大脳疲労に対する作用については全く知られておらず、例えば、長時間コンピュータを使用した場合や連続した思考による大脳疲労(計算能力、コンピュター作業、連続思考等の能力の低下)を回復させるための薬剤は全くない。
Chem. Pharm. Bull. Vol. 19, p1257-1261, 1971 薬学雑誌,Vol. 95, p892-895, 1975 特開平6−100442号公報 特開平8−73350号公報 特開2002−322063号公報 特開2001−187736号公報
As the pharmacological action of theanine, the action of antagonizing caffeine-induced convulsions and increase in momentum in mice (Non-patent Documents 1 and 2), inhibitory action on heart rate increase by isoproterenol, stress load Inhibition of blood pressure and heart rate increase due to urine (Patent Document 2), action of increasing Ca 2+ concentration in neurons in rats (Patent Document 3), reduced concentration after exercise by combined use with caffeine and arginine And the like (patent document 4) and the action of increasing catecholamine after exercise by combining caffeine and arginine (patent document 5) are known, but the effect on cerebral fatigue is completely known. For example, cerebral fatigue when using a computer for a long time or continuous thinking (computational ability) Konpyuta work, agents for recovering the reduction) of the ability of continuous thinking like no.
Chem. Pharm. Bull. Vol. 19, p1257-1261, 1971 Pharmaceutical Journal, Vol. 95, p892-895, 1975 Japanese Patent Laid-Open No. 6-100442 JP-A-8-73350 JP 2002-322063 A JP 2001-1887736 A

本発明の目的はヒトに固有の高度な精神的活動(例えば計算能力、コンピュター作業、連続思考等)による大脳疲労を回復させる薬剤、すなわち大脳疲労回復剤を提供するものである。   An object of the present invention is to provide an agent for recovering cerebral fatigue caused by advanced mental activities inherent in humans (for example, computational ability, computer work, continuous thinking, etc.), that is, a cerebral fatigue recovery agent.

そこで本発明者は、視覚の疲労を通じて大脳疲労の度合いを評価するフリッカーテストと連続計算能力を行うことで大脳疲労を生じさせるクレペリンテストとを組み合せ、作業継続による計算能力の低下、すなわち大脳疲労を回復させる成分を探索したところ、茶に含まれる成分である遊離アミノ酸の一種であるテアニンに強力な大脳疲労回復効果があることを見出した。   Therefore, the present inventor combined the flicker test that evaluates the degree of cerebral fatigue through visual fatigue and the Kraepelin test that causes cerebral fatigue by performing continuous calculation ability, and reduced the calculation ability by continuation of work, that is, cerebral fatigue. When searching for ingredients to recover, theanine, a kind of free amino acid contained in tea, was found to have a powerful cerebral fatigue recovery effect.

すなわち、本発明は、テアニンを有効成分とするヒトに固有の高度な精神的活動に基づく大脳疲労の回復剤を提供するものである。   That is, the present invention provides a recovery agent for cerebral fatigue based on a high level of mental activity unique to humans, comprising theanine as an active ingredient.

本発明によれば、長時間コンピュータ使用後、計算やその他の思考による精神疲労(大脳疲労)による能力低下を回復させることができる。また大脳疲労が想定される30〜40分前に服用しておくことで大脳疲労を予防することが期待される。   According to the present invention, after using a computer for a long time, it is possible to recover a decrease in ability due to mental fatigue (cerebral fatigue) due to calculations or other thoughts. It is expected to prevent cerebral fatigue by taking it 30 to 40 minutes before cerebral fatigue is expected.

本発明に用いられるテアニンは、茶の葉に含まれている旨味成分の一つであるグルタミン酸エチルアミド類である。このうち、L−グルタミン酸−γ−モノエチルアミド、すなわちL−テアニンが好ましい。   Theanine used in the present invention is glutamic acid ethylamide, which is one of the umami components contained in tea leaves. Among these, L-glutamic acid-γ-monoethylamide, that is, L-theanine is preferable.

本発明においてテアニンは、化学合成により得られたものを用いてもよいが、人の食経験の観点から植物由来の茶抽出物が好ましい。   In the present invention, theanine obtained by chemical synthesis may be used, but a plant-derived tea extract is preferred from the viewpoint of human eating experience.

本発明のヒトの大脳疲労回復剤におけるヒトに固有の高度な精神的活動とは、ヒト以外の動物には成し得ることのできない思考の論理的理解力を伴う精神的活動のことをいう。ヒトに固有の高度な精神的活動の具体的な内容としては、思考作業、計算作業、コンピューター作業等における連続作業が挙げられる。また、上記のヒトに固有の高度な精神的活動作業に伴う大脳疲労とは、個人差もあるが計算を含む思考作業等については20〜40分後、パソコン作業等については、1〜2時間後の状態をいう。   The high mental activity inherent in humans in the human cerebral fatigue recovery agent of the present invention refers to mental activities accompanied by a logical understanding of thought that cannot be achieved by animals other than humans. Specific contents of advanced mental activities unique to humans include continuous work in thinking work, calculation work, computer work, and the like. In addition, cerebral fatigue associated with the above-mentioned high-level mental activity tasks unique to human beings, although there are individual differences, after 20-40 minutes for thought tasks including calculations, 1-2 hours for computer tasks, etc. It refers to the later state.

本発明での、ヒトに固有の高度の精神的活動による大脳疲労の評価方法としては、クレペリンテストやフリッカーテスト等が挙げられる。
本発明で用いたクレペリンテストは、本来は精神検査を目的として用いられている連続加算作業であり、具体的には、横に並んだ隣り合わせの一桁の数字を順に足していく作業であり、高度な精神的活動の作業に伴う大脳疲労発生作業として位置づけることができる。ここでクレペリンテストは計算能力、コンピューター作業、連続思考等のモデル系として、定量化のために用いることができる。
Examples of the method for evaluating cerebral fatigue caused by a high level of mental activity inherent in humans in the present invention include the Kraepelin test and the flicker test.
The Kraepelin test used in the present invention is a continuous addition operation that is originally used for the purpose of mental examination, specifically, an operation of sequentially adding one-digit numbers next to each other side by side, It can be positioned as a task of generating cerebral fatigue associated with high mental activity. Here, the Kraepelin test can be used for quantification as a model system for computing power, computer work, continuous thinking and the like.

本発明で用いたフリッカーテストとは、任意の間隔で点滅する光源に対する視覚反応を測定する方法であるが、直接的には視器を通して大脳皮質の活動状態(疲労状態)を評価するものである。   The flicker test used in the present invention is a method for measuring the visual response to a light source flashing at an arbitrary interval, but directly evaluates the activity state (fatigue state) of the cerebral cortex through a visual instrument. .

通常、クレペリンテストにより生じた精神疲労(大脳疲労)は、フリッカーテスト測定によって疲労レベルが定量化できる。
本発明による疲労回復効果は、精神疲労(大脳疲労)として示されるフリッカーテスト値の低下がテアニンの摂取によって回復し、作業前の値まで回復することにある。
Normally, the fatigue level of cerebral fatigue caused by the Kraepelin test can be quantified by flicker test measurement.
The fatigue recovery effect according to the present invention is that the decrease in the flicker test value indicated as mental fatigue (cerebral fatigue) is recovered by ingestion of theanine and recovered to the value before the work.

本発明のヒトの大脳疲労回復剤で回復され得る大脳疲労には、運動負荷に起因する疲労及び疲労感は含まれず、主としてヒトが仕事や勉強の場面で行うデスクワーク等に伴う疲労が含まれる。   The cerebral fatigue that can be recovered with the human cerebral fatigue recovery agent of the present invention does not include fatigue and fatigue due to exercise load, but mainly includes fatigue associated with desk work or the like that is performed by a person at work or study.

本発明において、ヒトの大脳疲労回復剤の有効成分であるテアニンは、そのまま服用してもよいが、好ましくは薬学的に許容されうる塩、例えば塩酸塩の形で、賦形剤、担体等の薬品及び食品分野で慣用の補助成分、例えば乳糖、ショ糖、液糖、蜂蜜、ステアリン酸マグネシウム、オキシプロピルセルロース、各種ビタミン類、クエン酸、リンゴ酸、香料、無機塩などとともに、カプセル剤、錠剤、粉末剤、顆粒剤、ドリンク剤、注射剤、点滴剤等にすることができる。   In the present invention, theanine, which is an active ingredient of a human cerebral fatigue recovery agent, may be taken as it is, but preferably in the form of a pharmaceutically acceptable salt, for example, hydrochloride, as an excipient, carrier, etc. Auxiliary ingredients commonly used in the pharmaceutical and food fields, such as lactose, sucrose, liquid sugar, honey, magnesium stearate, oxypropylcellulose, various vitamins, citric acid, malic acid, fragrance, inorganic salts, capsules, tablets , Powders, granules, drinks, injections, drops, etc.

ドリンク剤の場合、必要に応じ、他の生理活性成分、ミネラル、ビタミン、ホルモン、栄養成分、香味剤等を混合することも可能である。また、緑茶系飲料、烏龍茶系飲料、紅茶系飲料、アイソトニック系飲料とすることもできる。   In the case of a drink, other physiologically active ingredients, minerals, vitamins, hormones, nutritional ingredients, flavoring agents and the like can be mixed as necessary. Moreover, it can also be set as a green tea type | system | group drink, a oolong tea type | system | group drink, a black tea type | system | group drink, and an isotonic type | system | group drink.

本発明のヒトの大脳疲労回復剤は、主にコンピュータ使用等に基づく計算能力の低下等の大脳機能低下の回復に有用であり、その服用量はテアニンとして成人1日あたり30〜2500mg、さらに40〜1000mg、特に40〜500mgが好ましい。本発明の大脳疲労回復剤は、ヒト固有の高度な精神的活動の前又は後に服用するのが好ましい。   The human cerebral fatigue recovery agent of the present invention is useful for recovering a decrease in cerebral function such as a decrease in calculation ability mainly based on computer use, and the dosage is 30 to 2500 mg per day for adults as theanine, and further 40 -1000 mg, especially 40-500 mg is preferred. The agent for recovering cerebral fatigue of the present invention is preferably taken before or after a high level of mental activity inherent in humans.

試験例1
被験者(35才、男性)に対してクレペリンテスト実施前に、作業前のフリッカー値を測定する目的でフリッカーテストを実施した。次にプラセボ飲料(水)を摂取した後、直ちにクレペリンテストを30分間行った。その後、クレペリンテスト終了直後を0分としてフリッカーテストを実施し、その後30分おきにフリッカー値の測定を実施した。実験結果を図1に示す。
Test example 1
A flicker test was performed on a subject (35 years old, male) to measure the flicker value before work before the Kraepelin test. Next, a placebo beverage (water) was ingested, and immediately followed by a Kraepelin test for 30 minutes. Thereafter, the flicker test was performed with 0 minute immediately after the end of the Kraepelin test, and then the flicker value was measured every 30 minutes. The experimental results are shown in FIG.

試験例2
被験者(35才、男性)に対してクレペリンテスト実施前に、作業前のフリッカー値を測定する目的でフリッカーテストを実施した。次にテアニン配合飲料(テアニン量50mg)を摂取した後、直ちにクレペリンテストを30分間行った。その後、クレペリンテスト終了直後を0分としてフリッカーテストを実施し、その後30分おきにフリッカー値の測定を実施した。実験結果を図2に示す。
Test example 2
A flicker test was performed on a subject (35 years old, male) to measure the flicker value before work before the Kraepelin test. Next, after ingesting a theanine-containing beverage (theanine amount 50 mg), a Kraepelin test was immediately performed for 30 minutes. Thereafter, the flicker test was performed with 0 minute immediately after the end of the Kraepelin test, and then the flicker value was measured every 30 minutes. The experimental results are shown in FIG.

図1及び2より、ヒトに固有の高度な精神的活動であるクレペリンテストの直前にテアニン50mgを服用した結果、精神的活動終了後に疲労度の指標であるフリッカー値の回復が確認された。   1 and 2, as a result of taking theanine 50 mg immediately before the Creperin test, which is an advanced mental activity unique to humans, recovery of the flicker value, which is an index of fatigue, was confirmed after the end of the mental activity.

本発明はヒトに固有な高度な精神疲労に基づく大脳疲労を回復させるものであるが、大脳疲労が想定される30〜40分前に服用しておくことで大脳疲労を予防することが期待される。   Although the present invention recovers cerebral fatigue based on a high level of mental fatigue inherent in humans, it is expected to prevent cerebral fatigue by taking it 30 to 40 minutes before cerebral fatigue is expected. The

プラセボ群のフリッカー値の変化を示す図である。It is a figure which shows the change of the flicker value of a placebo group. テアニン摂取群のフリッカー値の変化を示す図である。It is a figure which shows the change of the flicker value of a theanine intake group.

Claims (2)

テアニンを有効成分とするヒトに固有の高度な精神的活動に基づく大脳疲労の回復剤。   A therapeutic agent for cerebral fatigue based on advanced mental activities unique to humans, containing theanine as an active ingredient. 高度な精神的活動の前又は後に30〜2500mg/日/人摂取するためのものである請求項1記載の大脳疲労の回復剤。   The cerebral fatigue recovery agent according to claim 1, which is for ingestion of 30 to 2500 mg / day / person before or after high mental activity.
JP2003427401A 2003-12-24 2003-12-24 Agent for recovering cerebral fatigue Pending JP2005187344A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2003427401A JP2005187344A (en) 2003-12-24 2003-12-24 Agent for recovering cerebral fatigue

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2003427401A JP2005187344A (en) 2003-12-24 2003-12-24 Agent for recovering cerebral fatigue

Publications (1)

Publication Number Publication Date
JP2005187344A true JP2005187344A (en) 2005-07-14

Family

ID=34786687

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003427401A Pending JP2005187344A (en) 2003-12-24 2003-12-24 Agent for recovering cerebral fatigue

Country Status (1)

Country Link
JP (1) JP2005187344A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020036561A (en) * 2018-09-05 2020-03-12 株式会社 伊藤園 Green tea composition for inhibition of reduction of cognitive function associated with workload

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002322063A (en) * 2001-04-25 2002-11-08 Ito En Ltd Composition for relieving mental fatigue, composition for maintaining and enhancing concentration power, and composition for maintaining and enhancing mental vitality
JP2002370979A (en) * 2001-06-11 2002-12-24 Taiyo Kagaku Co Ltd Composition for improving mental concentration

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002322063A (en) * 2001-04-25 2002-11-08 Ito En Ltd Composition for relieving mental fatigue, composition for maintaining and enhancing concentration power, and composition for maintaining and enhancing mental vitality
JP2002370979A (en) * 2001-06-11 2002-12-24 Taiyo Kagaku Co Ltd Composition for improving mental concentration

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020036561A (en) * 2018-09-05 2020-03-12 株式会社 伊藤園 Green tea composition for inhibition of reduction of cognitive function associated with workload
JP7178836B2 (en) 2018-09-05 2022-11-28 株式会社 伊藤園 Green tea composition for suppressing cognitive function decline associated with workload

Similar Documents

Publication Publication Date Title
Higgins et al. Energy beverages: content and safety
Tipton et al. Exercise‐induced changes in protein metabolism
US10272091B2 (en) Theacrine-based supplement and method of use thereof
US11707465B2 (en) Theacrine-based supplement and method of use thereof in a synergistic combination with caffeine
JP2023145496A (en) Amino acid composition for treatment of neuronal injury
US20180221319A1 (en) Methods of treating seizure disorders and prader-willi syndrome
JPH0912454A (en) Theanine-containing composition
US20160303176A1 (en) Nutritional supplement
JPWO2006080086A1 (en) Composition for recovery or prevention of fatigue of central nervous system
US20040265473A1 (en) Ergogenic food compositons
Leahy et al. Branched‐Chain Amino Acid Plus Glucose Supplement Reduces Exercise‐Induced Delayed Onset Muscle Soreness in College‐Age Females
JP2007161675A (en) Fatigue-improving internal medicine
JP2006160721A (en) Agent for recovery from fatigue of cerebrum
JP6307329B2 (en) Sleep improver
JP2005187344A (en) Agent for recovering cerebral fatigue
CA2810793C (en) Sphaeranthus indicus derived ingredients and their compositions for enhancing physical performance and energy levels
JPWO2018207929A1 (en) Arterial blood oxygen saturation enhancer
AU2018270381B2 (en) Theacrine-based supplement and method of use thereof in a synergistic combination with caffeine
JP6578351B2 (en) Methods and compositions for improving concentration
US20220288083A1 (en) D9-caffeine compositions and uses thereof
US20130018061A1 (en) Method for Improving Exercise and Recovery From Exercise
US10105347B2 (en) Sphaeranthus indicus derived ingredients and their compositions for enhancing physical performance and energy levels
Piattoly L-glutamine supplementation: Effects on recovery from exercise
JP2007246507A (en) Prophylactic or curative composition for fatigue and method for preventing or treating fatigue
JP2008019190A (en) Volition-improving agent originated from natural product

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051220

A131 Notification of reasons for refusal

Effective date: 20090630

Free format text: JAPANESE INTERMEDIATE CODE: A131

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090819

A02 Decision of refusal

Effective date: 20100601

Free format text: JAPANESE INTERMEDIATE CODE: A02